FDA Approves Leucovorin Calcium Supplement Application by Ingenus Pharmaceuticals
The FDA has approved the supplemental application ANDA211132 for Leucovorin Calcium submitted by Ingenus Pharmaceuticals.
Company
Ingenus Pharmaceuticals
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The FDA's approval of Ingenus Pharmaceuticals' supplemental application for Leucovorin Calcium is significant as it introduces a new competitor in the supportive care market for oncology. This could lead to shifts in market dynamics and necessitate strategic adjustments from existing players.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timelines and any subsequent competitive responses from other manufacturers.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.